May 7th 2024
Data from the phase 3 CRC-PREVENT trial support the sensitivity of ColoSense in the detection of colorectal cancer.
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
2024 International Symposium of Gastrointestinal Oncology (ISGIO)
October 11-12, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®
View More
Patients With MSI-H/dMMR mCRC Saw Improvement in PFS, HRQoL with Pembrolizumab Monotherapy
January 16th 2021When compared with chemotherapy, patients with microsatellite-instability high/mismatch repair deficient metastatic colorectal cancer saw significant improvement in progression-free survival with the frontline use of pembrolizumab monotherapy, while demonstrating superior safety.
Pembrolizumab Plus Capecitabine and Bevacizumab Tolerable in Patients with MSS mCRC
January 15th 2021The phase 2 study presented at the 2021 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium reported a total of 2 responses at the interim analysis, meeting criteria to continue accrual.
Scott Kopetz, MD, PhD, on the Results of the SWOG S1406 Trial
January 15th 2021SWOG S1406 evaluated the use of irinotecan and cetuximab (Erbitux) with or without vemurafenib (Zelboraf) in patients with BRAF V600E-mutated metastatic colorectal cancer who had been previously treated with 1 or 2 regimens.
SWOG S1406 Finds Vemurafenib Combo With Irinotecan, Cetuximab Effective for BRAF-Mutatant CRC
January 12th 2021The study assessed the use of irinotecan and cetuximab (Erbitux) with or without vemurafenib (Zelboraf) in patients with BRAF V600E–mutated metastatic CRC who had been previously treated with 1 or 2 regimens.
Predictive Model Able to Predict Colorectal Cancer Risk Among Average-Risk Persons
December 21st 2020This new risk estimation model could help physicians determine whether an average risk patient’s specific risk indicates an at-home stool test would be a good screening option or suggests a colonoscopy may be the most appropriate option.
USMSTF Releases New Guidelines on Management of Malignant Colorectal Polyps
December 2nd 2020The guidance is intended to inform gastroenterologists of how to assess lesions for endoscopic features associated with cancer, discuss how these factors guide endoscopic management, and to outline the factors that frame whether to advise surgery after a malignant polyp has been endoscopically resected.
Adagrasib Shows Promise in Phase 1/2 Trial for KRAS G12C Mutated NSCLC, CRC, and Other Solid Tumors
November 24th 2020Adagrasib demonstrated an acceptable safety profile and promising clinical activity in pretreated patients with non-small cell lung cancer, colorectal cancer, and other solid tumors with a KRAS G12C mutation.
Molecular Profiling for Metastatic Colorectal Cancer and the Future of the Disease
September 25th 2020According to researchers, a “better understanding of the heterogeneity of mCRC, including primary tumor location, microsatellite instability (MSI) status, and other clinically actionable tumor mutations, is reshaping the therapeutic landscape.”
Frontline Pembrolizumab Improves Health-Related QOL in DNA Repair-Deficient Metastatic CRC
September 19th 2020Frontline pembrolizumab induced clinically meaningful improvements in the health-related quality of life of patients with microsatellite instability-high and/or mismatch repair-deficient metastatic colorectal cancer.